{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:27:12Z","timestamp":1780090032184,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.annder.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T00:12:49Z","timestamp":1471047169000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ulc\u00e8res des membres inf\u00e9rieurs d\u00e9velopp\u00e9s sous inhibiteurs de tyrosine kinase (sunitinib, nilotinib)"],"prefix":"10.1016","volume":"144","author":[{"given":"A.","family":"Roger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Sigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dakhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fargeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Couffinhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2016.06.009_bib0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mvr.2014.05.009","article-title":"In vitro and in vivo anti-angiogenic effects of hydroxyurea","volume":"94","author":"Lopes","year":"2014","journal-title":"Microvasc Res"},{"key":"10.1016\/j.annder.2016.06.009_bib0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtv.2013.08.002","article-title":"Cutaneous ulcers associated with hydroxyurea therapy","volume":"22","author":"Quattrone","year":"2013","journal-title":"J Tissue Viability"},{"key":"10.1016\/j.annder.2016.06.009_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jmv.2008.12.164","article-title":"Ulc\u00e8re chronique sous hydroxyur\u00e9e\u00a0: interrompre le traitement","volume":"34","author":"Michon-Pasturel","year":"2009","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.annder.2016.06.009_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","article-title":"Hydroxyurea-induced leg ulceration in 14\u00a0patients","volume":"128","author":"Best","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2016.06.009_bib0025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.annder.2008.02.025","article-title":"Complications cutan\u00e9es induites par l\u2019hydroxyur\u00e9e au long cours","volume":"135","author":"Dem","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2016.06.009_bib0030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2016.06.009_bib0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.annder.2007.12.006","article-title":"Effets secondaires cutan\u00e9s du soraf\u00e9nib et du sunitinib","volume":"135","author":"Autier","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2016.06.009_bib0040","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.3748\/wjg.v19.i31.5051","article-title":"Role of bevacizumab in colorectal cancer growth and its adverse effects: a review","volume":"19","author":"Pavlidis","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.annder.2016.06.009_bib0045","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.annder.2012.09.015","article-title":"Toxidermie \u00e0 l\u2019imatinib suivie d\u2019une toxidermie au nilotinib","volume":"139","author":"Lamchahab","year":"2012","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2016.06.009_bib0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies. Part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2016.06.009_bib0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annder.2016.06.009_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/2047-783X-16-11-491","article-title":"Sunitinib induced pyoderma gangrenosum-like ulcerations","volume":"16","author":"Akanay-Diesel","year":"2011","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.annder.2016.06.009_bib0065","unstructured":"Vidal Hoptimal. Sutent\u00ae. http:\/\/www.srvvidal:81\/showProduct.html?productId=73973 [site consult\u00e9 le 25\u00a0d\u00e9cembre\u00a02015]."},{"key":"10.1016\/j.annder.2016.06.009_bib0070","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.annder.2013.10.024","article-title":"Sunitinib et pyoderma gangrenosum","volume":"140","author":"Schmutz","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2016.06.009_bib0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-4632.2011.04952.x","article-title":"A case of pyoderma gangrenosum possibly associated with sunitinib treatment","volume":"52","author":"Ueharaguchi","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2016.06.009_bib0080","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1200\/JCO.2010.32.6165","article-title":"Pyoderma gangrenosum with the use of sunitinib","volume":"29","author":"Nadauld","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2016.06.009_bib0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2016.06.009_bib0090","unstructured":"Vidal Hoptimal. Tasigna\u00ae. http:\/\/www.srvvidal:81\/showProduct.html?productId=104451 [site consult\u00e9 le 25\u00a0d\u00e9cembre\u00a02015]."},{"key":"10.1016\/j.annder.2016.06.009_bib0095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2013.07.025","article-title":"Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia","volume":"69","author":"Delgado","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2016.06.009_bib0100","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.annder.2010.04.022","article-title":"Ulc\u00e9rations des membres inf\u00e9rieurs sous sunitinib","volume":"137","author":"Guyot-Caquelin","year":"2010","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2016.06.009_bib0105","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00228-013-1532-6","article-title":"Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors","volume":"69","author":"Faye","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.annder.2016.06.009_bib0110","first-page":"549","article-title":"Sorafenib: atypical cutaneous side effects","volume":"17","author":"Richetta","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2016.06.009_bib0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000200809","article-title":"Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation","volume":"82","author":"Feyerabend","year":"2009","journal-title":"Urol Int"},{"key":"10.1016\/j.annder.2016.06.009_bib0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jmv.2009.01.001","article-title":"Syndrome pied-main n\u00e9crotique sous antiangiog\u00e9niques chez une patiente porteuse d\u2019une acropathie ulc\u00e9romutilante de Th\u00e9venard","volume":"34","author":"Durant","year":"2009","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.annder.2016.06.009_bib0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.annder.2016.06.009_bib0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.critrevonc.2014.06.003","article-title":"Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis","volume":"92","author":"Abdel-Rahman","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annder.2016.06.009_bib0135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/wound.2013.0496","article-title":"Anti-angiogenic drugs: involvement in cutaneous side effects and wound-healing complication","volume":"3","author":"Bodnar","year":"2014","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.annder.2016.06.009_bib0140","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annder.2016.06.009_bib0145","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.annder.2016.06.009_bib0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quintas-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.annder.2016.06.009_bib0155","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annder.2016.06.009_bib0160","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1038\/bcj.2014.66","article-title":"Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion","volume":"4","author":"Maurizot","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annder.2016.06.009_bib0165","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.annder.2016.06.009_bib0170","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.23442","article-title":"Nilotinib treatment-associated cerebrovascular disease and stroke","volume":"88","author":"Coon","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annder.2016.06.009_bib0175","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963816303362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963816303362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:04:26Z","timestamp":1758971066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963816303362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0151963816303362"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2016.06.009","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ulc\u00e8res des membres inf\u00e9rieurs d\u00e9velopp\u00e9s sous inhibiteurs de tyrosine kinase (sunitinib, nilotinib)","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}